Autologous Antigen-Specific Immunotherapy (AASI) Precision Immune Re-education in Autoimmunity and Beyond

Autologous Antigen-Specific Immunotherapy (AASI) is redefining how we treat autoimmune and immune-mediated diseases, from Type 1 diabetes and multiple sclerosis to allergies, organ transplantation, and even cancer.

In this comprehensive new article, discover how AASI leverages a patient’s own immune cells to restore immune tolerance with precision, safety, and potential applications across diverse clinical fields.

🔬 Key Highlights:

✔️ Explains how AASI targets disease-causing antigens while preserving normal immunity
✔️ Showcases cutting-edge AASI platforms: tolerogenic dendritic cells (tolDCs), nanoparticles, peptide conjugates, and CAR-Tregs
✔️ Explores clinical potential for autoimmune diseases (T1D, MS, SLE, RA), allergies, transplant rejection, and cancer
✔️ Highlights challenges and future directions in biomarker profiling, AI-guided antigen selection, and personalized delivery systems
✔️ Emphasizes safety and selectivity as the next frontier in immune tolerance therapy

This review calls for a shift from immunosuppression to immune education toward a future of targeted, lasting, and safer interventions.

🧬 AASI isn’t just a treatment. It’s a paradigm shift in immunotherapy.

MORE PUBLICATIONS:
https://european-wellness.eu/publications/